CAS: 263707-16-0

ESI-09 is a novel drug candidate that has been shown to have synergistic effects with chemotherapeutic agents in the treatment of cancer. It is a potential drug target for cancer, and its anticancer activity may be due to its ability to reduce oxidative stress by activating antioxidant enzymes. ESI-09 has antioxidative properties and decreases the mitochondrial membrane potential, which leads to increased ATP levels. ESI-09 also has the ability to cause cell death by inhibiting aerobic glycolysis, which may be due to its inhibitory effects on the polymerase chain reaction (PCR).

ESI-09

ESI-09

Applications ESI 09 acts as an EPAC inhibitor, preventing EPAC-mediated insulin release form β-pancreatic cells. Selective control for EPAC over PKA and decreases migration and invasion of AsPc-1 and PANC-1 pancreatic cancer cells. References Tao, X. et al.: J. Virol., 88, 3902 (2014); Almahariq, M. et al.: Mol. Pharm., 83, 122 (2013);

ESI-09 is a new-typel noncyclic nucleotide EPAC antagonist.The IC50 values of ESI-09 for EPAC1 and EPAC2 is 3.2 and 1.4 μM, respectively.